ALS is a complex neurodegenerative disease, but the causes remain poorly understood and there are few effective therapies available. There is an urgent need for large-scale, collaborative efforts to identify useful biofluid biomarkers that can guide researchers about its onset, progression, and response to effective therapies.
To achieve these goals, the NIH has established a transformative national ALS clinical research consortium called Access for All in ALS (ALL ALS). This new consortium is a multi-institutional effort and aims to disrupt the ALS clinical research landscape in the U.S. It will operationalize recommendations of the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS) Public Private Partnership. This grant is made possible by the Accelerating Access to Critical Therapies for ALS Act, which was signed into law in December 2021.